Table 1.
Baseline characteristics of participants in groups according to their response to anti-VEGF treatment
| Response to anti-VEGF loading dose | Good | Partial | Non-response | P value |
| No. of patients, n | 28 | 27 | 10 | |
| Demographic characteristics | ||||
| Age, mean (95% CI) | 79.5 (76.9 to 82.2) | 75.9 (72.7 to 79.0) | 71.1 (67.4 to 74.8) | 0.007* |
| Females, % | 60.7 | 51.9 | 40.0 | 0.534† |
| Body mass index, mean (95% CI) | 25.6 (23.7 to 27.3) | 26.1 (24.0 to 28.3) | 25.1 (21.0 to 29.2) | 0.840* |
| Smoking status | ||||
| Current, % | 17.9 | 29.6 | 40.0 | 0.462† |
| Former, % | 46.4 | 44.4 | 50.0 | |
| Never, % | 35.7 | 25.9 | 10.0 | |
| Alcohol (units/week), median (IQR) | 3.8 (0.5–9) | 6.0 (1.0–10.0) | 3.5 (1.0–10.0) | 0.828‡ |
| Regular exercise, % | 57 | 63 | 70 | 0.789† |
| Hypertension, % | 64 | 41 | 40 | 0.174† |
| Hypercholesterolaemia, % | 43 | 19 | 20 | 0.125† |
| Cardiovascular disease, % | 32 | 22 | 30 | 0.702† |
| Type 2 diabetes, % | 18 | 4 | 0 | 0.152† |
| Retinal characteristics | ||||
| Central retinal thickness, µm, median (IQR) | 385 (313–476) | 432 (338–552) | 412 (351–550) | 0.475‡ |
| Best-corrected visual acuity (ETDRS letters), median (IQR) | 69 (56–79) | 63 (50–73) | 61.5 (50–73) | 0.264‡ |
| Intraretinal oedema, % | 75 | 52 | 60 | 0.294† |
| Subretinal oedema, % | 71 | 93 | 90 | 0.063† |
| Treatment | ||||
| Aflibercept, % | 71 | 48 | 50 | 0.187† |
| Ranibizumab, % | 29 | 52 | 50 |
*Analysis of variance.
†Fisher’s exact test.
‡Kruskal-Wallis test.
VEGF, vascular endothelial growth factor.